https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-ziihera-gea-treatment BiopharmaWatch en 2026-08-31T13:07:00.000Z Riassunto: BeOne Medicines annuncia i nuovi dati sulla sopravvivenza di Fase 3 a supporto del beneficio dei regimi a base di ZIIHERA nel trattamento di prima linea dei tumori gastroesofagei (GEA) HER2-positivi https://www.biopharmawatch.com/news/BIO/bio-rad-fireside-chat-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T13:00:00.000Z Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/AIM/aim-immunotech-patent-ampligen-pembrolizumab-cancer BiopharmaWatch en 2026-08-31T12:51:00.000Z AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 https://www.biopharmawatch.com/news/PFSA/profusa-compliance-nasdaq-requirement BiopharmaWatch en 2026-08-31T12:50:00.000Z Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement https://www.biopharmawatch.com/news/ONMD/onemednet-iRWD-platform-ai-drug-development BiopharmaWatch en 2026-08-31T12:35:00.000Z OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-september-investor-conference BiopharmaWatch en 2026-08-31T12:30:00.000Z Allogene Therapeutics Announces Participation in September Investor Conference https://www.biopharmawatch.com/news/HYPR/hyperfine-lake-street-conference-participation BiopharmaWatch en 2026-08-31T12:15:00.000Z Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference https://www.biopharmawatch.com/news/AMRN/amarin-esc-congress-2026-findings BiopharmaWatch en 2026-08-31T12:15:00.000Z Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-ttx-mc138-breast-cancer-study BiopharmaWatch en 2026-08-31T12:05:00.000Z TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis https://www.biopharmawatch.com/news/KLRS/kalaris-present-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T12:00:09.000Z Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-morgan-stanley-conference BiopharmaWatch en 2026-08-31T12:00:07.000Z OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/GEHC/ge-healthcare-photonova-spectra-ce-mark BiopharmaWatch en 2026-08-31T12:00:00.000Z GE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international access https://www.biopharmawatch.com/news/ABBV/abbvie-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-michael-grasher-cfo BiopharmaWatch en 2026-08-31T12:00:00.000Z Teladoc Health Appoints Michael Grasher as Chief Financial Officer https://www.biopharmawatch.com/news/AEON/aeon-biopharma-lake-street-capital-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-bezisterim-long-covid BiopharmaWatch en 2026-08-31T12:00:00.000Z BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID https://www.biopharmawatch.com/news/XAIR/beyond-air-fda-breakthrough-lungfit-go-ntm-pd BiopharmaWatch en 2026-08-31T12:00:00.000Z Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-fda-type-d-meeting-cad-1005 BiopharmaWatch en 2026-08-31T12:00:00.000Z Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PTGX/fda-approval-mimrylo-rusfertide-polycythemia-vera BiopharmaWatch en 2026-08-31T12:00:00.000Z US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-canada BiopharmaWatch en 2026-08-31T11:55:00.000Z Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-opioid-overdose-awareness BiopharmaWatch en 2026-08-31T11:54:00.000Z Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day https://www.biopharmawatch.com/news/AGEN/agenus-participate-september-investor-conferences BiopharmaWatch en 2026-08-31T11:30:00.000Z Agenus to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/KPTI/karyopharm-submits-snda-fda-xpovio-ruxolitinib-myelofibrosis BiopharmaWatch en 2026-08-31T11:30:00.000Z Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-ndas-qtorin-rapamycin BiopharmaWatch en 2026-08-31T11:30:00.000Z Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-08-31T11:00:07.000Z Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-conference-participation-2026 BiopharmaWatch en 2026-08-31T11:00:00.000Z Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-financial-results-h1-2026 BiopharmaWatch en 2026-08-31T11:00:00.000Z Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-q2-2026-results-update BiopharmaWatch en 2026-08-31T11:00:00.000Z BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LH/labcorp-global-trial-connect-enhancements BiopharmaWatch en 2026-08-31T11:00:00.000Z Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-summit-phase-3-trial-axs-05 BiopharmaWatch en 2026-08-31T11:00:00.000Z Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation https://www.biopharmawatch.com/news/ASND/ascendis-biomarin-global-settlement-yuviwel BiopharmaWatch en 2026-08-31T11:00:00.000Z Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) https://www.biopharmawatch.com/news/TELA/tela-bio-coo-cfo-transition-cost-reduction BiopharmaWatch en 2026-08-31T11:00:00.000Z TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative https://www.biopharmawatch.com/news/HLF/herbalife-ceo-transition-stephan-gratziani BiopharmaWatch en 2026-08-31T10:50:00.000Z Herbalife Announces Planned CEO Transition https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-ziihera-data-her2-cancer BiopharmaWatch en 2026-08-31T10:00:00.000Z BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-fda-type-c-meeting-ide849 BiopharmaWatch en 2026-08-31T10:00:00.000Z IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer https://www.biopharmawatch.com/news/NUTX/nutex-health-hospitals-community-honors-q2-2026 BiopharmaWatch en 2026-08-31T09:30:00.000Z Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-fda-review-avt80-biosimilar BiopharmaWatch en 2026-08-31T08:30:00.000Z Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations https://www.biopharmawatch.com/news/AMGN/amgen-repatha-reduces-death-risk-heart-attack-stroke BiopharmaWatch en 2026-08-31T07:18:00.000Z AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-31 BiopharmaWatch en 2026-08-31T07:15:24.149Z Biotech Catalysts to Watch: Key Developments Ahead in Q4 2026 https://www.biopharmawatch.com/news/BMRN/biomarin-settlement-ascendis-yuviwel-royalties BiopharmaWatch en 2026-08-31T06:00:00.000Z BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data-rnai-therapy BiopharmaWatch en 2026-08-31T04:46:00.000Z Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen https://www.biopharmawatch.com/news/ALNY/alnylam-esc-2026-rnai-therapy-data BiopharmaWatch en 2026-08-31T04:35:00.000Z Riassunto: Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici https://www.biopharmawatch.com/news/ALNY/alnylam-esc-2026-transthyretin-silencing-data BiopharmaWatch en 2026-08-31T04:35:00.000Z Resumen: Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans... https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-rnai-ttr-silencing BiopharmaWatch en 2026-08-31T04:35:00.000Z Samenvatting: Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen https://www.biopharmawatch.com/blog/biotech-stocks-hedge-funds-are-buying-q2-2026 BiopharmaWatch en 2026-08-30T22:41:03.361Z The 28 Biotech Stocks Hedge Funds Are Buying and Holding in 2026 (Q2 13F Special Report) https://www.biopharmawatch.com/news/ARWR/arrowhead-phase-3-shasta-3-4-plozasiran-results BiopharmaWatch en 2026-08-30T15:30:00.000Z Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data BiopharmaWatch en 2026-08-30T12:23:00.000Z Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings https://www.biopharmawatch.com/news/BMY/bmy-camzyos-long-term-efficacy-esc-congress-2026 BiopharmaWatch en 2026-08-29T15:00:00.000Z Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CYTK/cytokinetics-acacia-hcm-maple-hcm-results-esc-2026 BiopharmaWatch en 2026-08-29T14:30:00.000Z Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026